11 May 2015

Dihydrocodeine Tablets (Dihydrocodeine Tartrate) - United Kingdom

ATC: N02AA
NERVOUS SYSTEM
ANALGESICS
OPIOIDS
NATURAL OPIUM ALKALOIDS
Dihydrocodeine Tablets BP

Generic Matches for Dihydrocodeine Tartrate (2)
DHC Continus prolonged release tablets 60mg, 90mg and 120 mg
Dihydrocodeine Tablets BP 30mg

Last Updated on 11 May 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Dihydrocodeine Tablets BP Indication

As an analgesic for the relief of moderate to severe pain. Dihydrocodeine Tablets 30mg are indicated in all painful conditions where an alert patient is desired, eg sciatica, osteo-arthritis, chronic rheumatoid arthritis, arthritis of the spine, peripheral vascular disease, post-herpetic neuralgia, Paget's disease, malignant disease, post-operative pain.

Because dihydrocodeine, in the recommended doses, causes little or no respiratory depression, its use in the treatment of post-operative pain may reduce the risk of chest complications.

 

Dihydrocodeine Tablets BP Generic Name

Dihydrocodeine Tartrate

Type

POM

Summary Product Characteristics (SPCs) Links
SPC - Dihydrocodeine Tablets BP 30mg (external site)

Related Learning Zones

CLL Knowledge Centre and CME

CLL Knowledge Centre and CME

The Chronic Lymphocytic Leukaemia (CLL) Knowledge Centre contains useful information arranged within four main sections: ‘Disease Awareness’, ‘Events’, ‘Resources’, and 'CME'. Healthcare professionals will find information on pathophysiology, signs and symptoms of CLL, diagnosis, prognosis, treatment and management options, an upcoming events calendar and an external links listing,

The CME activity ‘Treatment Optimisation in Chronic Lymphocytic Leukaemia’ has been EACCME-accredited and awarded 1 CME credit. Test your knowledge by answering quiz questions based on patient case study scenarios.

IL-17A in Psoriasis

IL-17A in Psoriasis

IL-17A in Psoriasis is intended for healthcare professionals involved in the treatment and management of patients with psoriasis. This resource has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A. Users can expect to find sections containing expert videos, clinical slide decks, congress highlights, key publications and links to useful resources.

This resource has been developed in collaboration with Novartis Pharma AG.

Dihydrocodeine Tablets Marketing Information

Dihydrocodeine Tablets Generic Name
Dihydrocodeine Tartrate
Marketing Company
Actavis UK Limited
Drug Type
POM
Date of Issue, Marketing Authority 01/10/1986

Related Drugs - Pain Management

Back to top